Welcome to our dedicated page for Oaktree Acquisition III SEC filings (Ticker: OACCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oaktree Acquisition Corp III’s life-sciences mandate makes its SEC filings anything but routine. One 8-K may reveal a game-changing biotech target; the next S-4 spans hundreds of pages on sponsor promote, redemption math, and warrant dilution. Sifting through those documents to spot key timelines or understand how OACCW warrants convert can be daunting.
Stock Titan’s AI solves that problem. We stream every filing straight from EDGAR—Form 8-K for merger announcements, 10-Q once the business combination closes, even the proxy statement on executive compensation—and generate plain-English summaries within seconds. Want to track Oaktree Acquisition Corp III insider trading Form 4 transactions or get a breakdown of trust-account movements? Our algorithms highlight the numbers and flag unusual activity, so you don’t waste hours combing through footnotes.
Use this page to:
- Receive real-time alerts for Oaktree Acquisition Corp III Form 4 insider transactions and warrant exercises
- See the Oaktree Acquisition Corp III quarterly earnings report 10-Q filing—with AI commentary on post-merger cash burn
- Read an Oaktree Acquisition Corp III annual report 10-K simplified for long-term risk factors
- Understand every Oaktree Acquisition Corp III 8-K material events explained, from extension votes to definitive merger agreements
Whether you’re evaluating redemption scenarios, following Oaktree Acquisition Corp III executive stock transactions Form 4, or simply looking for an Oaktree Acquisition Corp III earnings report filing analysis, our platform keeps the complexities of SPAC disclosures manageable. Understanding Oaktree Acquisition Corp III SEC documents with AI—that’s the edge professional investors need.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report shared beneficial ownership of 803,487 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences, representing 4.1% of the class. Both reporting persons indicate zero sole voting and dispositive power and shared voting and dispositive power of 803,487, showing the stake is held jointly rather than under exclusive control by either entity.
The filing states the securities are held in the ordinary course of business and were not acquired to change or influence control. A joint filing agreement is attached and an exhibit clarifies that The Goldman Sachs Group, Inc. is a parent holding company and Goldman Sachs & Co. LLC is a subsidiary broker-dealer and registered investment adviser. The filing is classified as ownership of 5% or less of the class.
Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to complete a business combination; it has not selected a target. The company completed its Initial Public Offering and private placement and holds $197,576,768 in a Trust Account as of June 30, 2025, intended to fund a Business Combination. For the six months ended June 30, 2025 the company reported $3,533,134 net income, driven by $4,247,746 of interest income on Trust Account funds and offset by $714,612 of general and administrative expenses.
Outside the Trust Account the company had $1,385,359 in cash and $441,907 of working capital. There were 19,199,029 Class A shares subject to possible redemption at a redemption value of $10.29 per share. Material items include a $6,719,660 deferred underwriting fee payable from the Trust Account and sponsor provisions that may require the sponsor to indemnify the Trust Account, although the company notes the sponsor's only assets may be company securities. The company experienced a management change with the CFO resigning and a successor appointed on June 3, 2025.
FAQ
What is the current stock price of Oaktree Acquisition III (OACCW)?
